DCIS-met model for predicting metastases in patients with biopsy-proven DCI - Evidencio
DCIS-met model for predicting metastases in patients with biopsy-proven DCIS
This model calculates the predicted risk for lymph node metastasis after a DCIS diagnosis by biopsy.

The model uses pre-operatively known risk factors: age, the detection mode, the biopsy DCIS grade, palpability of the tumour, the BI-RADS score and the presence of a histologic suspected invasive component.
Les auteurs de la recherche: Claudia J.C. Meurs, Joost van Rosmalen, Marian B.E. Menke-Pluijmers, Sabine Siesling, Pieter J. Westenend
Version: 1.24
  • Public
  • Chirurgie
  • {{ modelType }}
  • Algorithme
  • Détails
  • Valider
  • Sauvegarder l'entrée
  • Entrée de la charge
  • {{ toolbarErrorMessage }}

Affichage
Unités

{{ section.title }}

{{ section.description }}

Calculer le résultat

Définir d'autres paramètres pour effectuer le calcul

Predicted risk of metastases:

{{ resultSubheader }}
{{ $t('download_result_availability') }}
slide-left-right {{ $t('scroll_chart') }}
{{ chart.title }}
Intervalle de résultats {{ additionalResult.min }} à {{ additionalResult.max }}

Informations conditionnelles

Votre ou vos saisies ont été modifiées. Veuillez mettre à jour votre résultat. Mettre à jour

Overall information regarding the model:
The model was based on 2,892 cases of DCIS and 127 events of lymph node metastases. The predicted risks in our study ranged from 0.4% to 40.4%, the mean was 4.4% and the median was 2.8%. The c-index was 0.745 and it was 0.748 after correction for optimism by bootstrapping. In this study the sensitivity was the rate of metastasis that was correctly predicted as high-risk and 1-specificity was the rate of no-metastasis that was falsely predicted as high-risk. The calibration plot had a slope of 1.029 and an intercept of 0.090. The decision curve analysis showed that the model has a higher benefit than performing the sentinel lymph node biopsy for all patients. Below the prediction cut-off point of 25% the model has a higher benefit than performing the sentinel lymph node biopsy for none patients.

The validation cohort consisted of the 2,269 patients. In total, 53 (2.2%) had metastasis. The calibration plot showed that the observed proportions were lower than the predicted proportions. The AUC in the validation cohort was 0.741 (95% confidence interval 0.662 to 0.820). The maximum value of the Youden’s index was found at a predicted risk of 3.5%, with a sensitivity of 71.4% and a specificity of 70.6%.

Patients with previous ipsilateral DCIS or invasive breast cancer, patients with biopsy-proven micro-invasive cancer and patients who underwent excisional biopsy were excluded from the cohorts on which the model was developed or validated.

How to use the model:
The model can be used to calculate the individual risk of lymph node metastasis for patients with biopsy-proven DCIS.

{{ file.classification }}
PRO
Note
Les notes ne sont visibles que dans le téléchargement des résultats et ne sont pas sauvegardées par Evidencio.

Ce algorithme est fourni à des fins d'éducation, de formation et d'information. Il ne doit pas être utilisé pour aider à la prise de décision médicale ou pour fournir des services médicaux ou de diagnostic. Lire l'intégralité de notre disclaimer.

Algorithmes sous-jacents Une partie de
Commentaires
Commentaire
Veuillez saisir un commentaire
Les commentaires sont visibles par tous

Retour d'information sur le algorithme

Pas encore de retour d'information 1 Commentaire {{ model.comments.length }} Commentaires
Sur {{ comment.created_at }} {{ comment.user.username }} un auteur qui n'est plus enregistré a écrit :
{{ comment.content }}
logo

Veuillez vous connecter pour activer les fonctions d'impression d'Evidencio

Pour utiliser les fonctions d'impression d'Evidencio, vous devez être connecté.
Si vous n'avez pas de compte communautaire Evidencio, vous pouvez créer un compte personnel gratuit à:

https://www.evidencio.com/registration

Résultats imprimés - Exemples 2026-11-15 01:45


Avantages du compte communautaire Evidencio


With an Evidencio Community account you can:

  • Create and publish your own prediction algorithms.
  • Share your prediction algorithms with your colleagues, research group, organization or the world.
  • Review and provide feedback on algorithms that have been shared with you.
  • Validate your algorithms and validate algorithms from other users.
  • Find algorithms based on Title, Keyword, Author, Institute, or MeSH classification.
  • Use and save prediction algorithms and their data.
  • Use patient specific protocols and guidelines based on sequential algorithms and decision trees.
  • Stay up-to-date with new algorithms in your field as they are published.
  • Create your own lists of favorite algorithms and topics.

A personal Evidencio account is free, with no strings attached!
Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction algorithms.


Clause de non-responsabilité : les calculs ne doivent jamais dicter les soins aux patients et ne remplacent pas le jugement d'un professionnel.